Opioid Drugs: Global Markets to 2023
Report Scope:
The current report offers a detailed picture of the prescription opioid drug market. Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included. The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.
This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.
The report details market shares of opioid drugs based on product and geography. Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others. Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
The current report offers a detailed picture of the prescription opioid drug market. Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included. The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.
This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.
The report details market shares of opioid drugs based on product and geography. Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others. Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
- 20 data tables and 38 additional tables
- An overview of the global market for opioid drugs
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor and Kappa receptor
- Details of technological advancement for new opioid formulation to reduce the risk of drug abuse
- Case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
- Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
- Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
- Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Overview: Opioid Drugs
Types of Opioids
Receptor Targets of Opioid Drugs
Mu Receptor
Delta Receptor
Kappa Receptor
Significant Events Related to Opioid Misuse and Abuse
Technology Advancements in Opioid Drugs
Abuse Deterrent Approaches
Abuse-Deterrent Technologies
Novel Drug Delivery Systems
Therapeutic Applications of Opioid Drugs
Cancer Pain Management
Surgical Pain Management
Opioid Use Disorder
Prescription Drug Monitoring Programs (PDMPs)
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Rising Prevalence of Chronic Pain
Rise in Palliative Care for Patients Suffering from Pain
New Opioid Formulation to Reduce the Risk of Abuse
Increasing Incidence of Road Accidents and Surgical Procedures
Market Restraints
Widespread Misuse of Opioids
Increasing Incidence of Death Related to Opioid Overdose
Growing Number of Lawsuits against Opioid Manufacturers
CHAPTER 5 MARKET BREAKDOWN BY PRODUCT
Global Market for Opioid Drugs by Product
Buprenorphine
Market Size and Forecast
Market Analysis
Fentanyl
Market Size and Forecast
Market Analysis
Hydrocodone
Market Size and Forecast
Market Analysis
Morphine
Market Size and Forecast
Market Analysis
Oxycodone
Market Size and Forecast
Market Analysis
Tramadol
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Opioid Drugs by Region
North America
United States
Canada and Mexico
Europe
Germany
U.K.
France
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
CHAPTER 7 REGULATORY ENVIRONMENT
Regulations in the U.S.
New Drug Approvals
The FDA Modernization Act of 1997
New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
Risk Evaluation and Mitigation Strategy (REMS)
Schedules Under the Controlled Substances Act
Federal Initiatives to Address Non-medical Use of Prescription Opioids
FDA's Opioid Policy Work Plan
CDC Guidelines for Prescribing Opioids for Chronic Pain
CHAPTER 8 PIPELINE ANALYSIS
Overview of the Drug Development Process
Pipeline Analysis of Opioid Drugs
CHAPTER 9 COMPETITIVE LANDSCAPE
Current Market Scenario
Key Strategies Adopted by Market Players
Influence of Generic Drugs on the Global Opioid Drug Market
Significant Industry Events and Developments
CHAPTER 10 COMPANY PROFILES
ACURA PHARMACEUTICALS INC.
Company Overview
Product Portfolio
ALLERGAN PLC
Company Overview
Financials
Product Portfolio
APOTEX INC.
Company Overview
Product Portfolio
ASSERTIO THERAPEUTICS INC. (DEPOMED INC.)
Company Overview
Financials
Product Portfolio
Developments and Strategies
BIODELIVERY SCIENCES INTERNATIONAL INC.
Company Overview
Financials
Product Portfolio
Developments and Strategies
CIPHER PHARMACEUTICALS INC.
Company Overview
Product Portfolio
COLLEGIUM PHARMACEUTICAL INC.
Company Overview
Product Portfolio
DAIICHI SANKYO INC.
Company Overview
Product Portfolio
EGALET CORP.
Company Overview
Product Portfolio
ENDO INTERNATIONAL PLC
Company Overview
Financials
Product Portfolio
Developments and Strategy
HIKMA PHARMACEUTICALS PLC
Company Overview
Product Portfolio
INDIVIOR PLC
Company Overview
INSYS THERAPEUTICS INC.
Company Overview
Product Portfolio
JOHNSON & JOHNSON
Company Overview
Product Portfolio
KEMPHARM INC.
Company Overview
Product Portfolio
LANNETT CO. INC.
Company Overview
Financials
Product Portfolio
LUPIN LTD.
Company Overview
Product Portfolio
MALLINCKRODT
Company Overview
Product Portfolio
MYLAN NV
Company Overview
Financials
Product Portfolio
Developments and Strategies
OREXO AB
Company Overview
Product Portfolio
PFIZER INC.
Company Overview
Product Portfolio
Developments and Strategies
PURDUE PHARMA LP
Company Overview
Product Portfolio
Developments and Strategies
PERNIX THERAPEUTICS
Company Overview
Product Portfolio
Developments and Strategies
SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
Company Overview
Financials
Product Portfolio
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Financials
Product Portfolio
CHAPTER 11 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Overview: Opioid Drugs
Types of Opioids
Receptor Targets of Opioid Drugs
Mu Receptor
Delta Receptor
Kappa Receptor
Significant Events Related to Opioid Misuse and Abuse
Technology Advancements in Opioid Drugs
Abuse Deterrent Approaches
Abuse-Deterrent Technologies
Novel Drug Delivery Systems
Therapeutic Applications of Opioid Drugs
Cancer Pain Management
Surgical Pain Management
Opioid Use Disorder
Prescription Drug Monitoring Programs (PDMPs)
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Rising Prevalence of Chronic Pain
Rise in Palliative Care for Patients Suffering from Pain
New Opioid Formulation to Reduce the Risk of Abuse
Increasing Incidence of Road Accidents and Surgical Procedures
Market Restraints
Widespread Misuse of Opioids
Increasing Incidence of Death Related to Opioid Overdose
Growing Number of Lawsuits against Opioid Manufacturers
CHAPTER 5 MARKET BREAKDOWN BY PRODUCT
Global Market for Opioid Drugs by Product
Buprenorphine
Market Size and Forecast
Market Analysis
Fentanyl
Market Size and Forecast
Market Analysis
Hydrocodone
Market Size and Forecast
Market Analysis
Morphine
Market Size and Forecast
Market Analysis
Oxycodone
Market Size and Forecast
Market Analysis
Tramadol
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Opioid Drugs by Region
North America
United States
Canada and Mexico
Europe
Germany
U.K.
France
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
CHAPTER 7 REGULATORY ENVIRONMENT
Regulations in the U.S.
New Drug Approvals
The FDA Modernization Act of 1997
New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
Risk Evaluation and Mitigation Strategy (REMS)
Schedules Under the Controlled Substances Act
Federal Initiatives to Address Non-medical Use of Prescription Opioids
FDA's Opioid Policy Work Plan
CDC Guidelines for Prescribing Opioids for Chronic Pain
CHAPTER 8 PIPELINE ANALYSIS
Overview of the Drug Development Process
Pipeline Analysis of Opioid Drugs
CHAPTER 9 COMPETITIVE LANDSCAPE
Current Market Scenario
Key Strategies Adopted by Market Players
Influence of Generic Drugs on the Global Opioid Drug Market
Significant Industry Events and Developments
CHAPTER 10 COMPANY PROFILES
ACURA PHARMACEUTICALS INC.
Company Overview
Product Portfolio
ALLERGAN PLC
Company Overview
Financials
Product Portfolio
APOTEX INC.
Company Overview
Product Portfolio
ASSERTIO THERAPEUTICS INC. (DEPOMED INC.)
Company Overview
Financials
Product Portfolio
Developments and Strategies
BIODELIVERY SCIENCES INTERNATIONAL INC.
Company Overview
Financials
Product Portfolio
Developments and Strategies
CIPHER PHARMACEUTICALS INC.
Company Overview
Product Portfolio
COLLEGIUM PHARMACEUTICAL INC.
Company Overview
Product Portfolio
DAIICHI SANKYO INC.
Company Overview
Product Portfolio
EGALET CORP.
Company Overview
Product Portfolio
ENDO INTERNATIONAL PLC
Company Overview
Financials
Product Portfolio
Developments and Strategy
HIKMA PHARMACEUTICALS PLC
Company Overview
Product Portfolio
INDIVIOR PLC
Company Overview
INSYS THERAPEUTICS INC.
Company Overview
Product Portfolio
JOHNSON & JOHNSON
Company Overview
Product Portfolio
KEMPHARM INC.
Company Overview
Product Portfolio
LANNETT CO. INC.
Company Overview
Financials
Product Portfolio
LUPIN LTD.
Company Overview
Product Portfolio
MALLINCKRODT
Company Overview
Product Portfolio
MYLAN NV
Company Overview
Financials
Product Portfolio
Developments and Strategies
OREXO AB
Company Overview
Product Portfolio
PFIZER INC.
Company Overview
Product Portfolio
Developments and Strategies
PURDUE PHARMA LP
Company Overview
Product Portfolio
Developments and Strategies
PERNIX THERAPEUTICS
Company Overview
Product Portfolio
Developments and Strategies
SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
Company Overview
Financials
Product Portfolio
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Financials
Product Portfolio
CHAPTER 11 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Opioid Drug Market, by Product, Through 2023
Table 1: Analgesic Effects of Drugs at Different Opioid Receptors
Table 2: Timeline of Selected FDA Activities and Events Related to Opioid Misuse and Abuse, 1911-2018
Table 3: FDA Approved Opioids with ADF Labeling
Table 4: Opioid Lawsuit Settlements, 2015-2027
Table 5: Global Opioid Drug Market, by Product, Through 2023
Table 6: Global Buprenorphine Drug Market, by Region, Through 2023
Table 7: Global Fentanyl Drug Market, by Region, Through 2023
Table 8: Global Hydrocodone Drug Market, by Region, Through 2023
Table 9: Global Morphine Drug Market, by Region, Through 2023
Table 10: Global Oxycodone Drug Market, by Region, Through 2023
Table 11: Global Tramadol Drug Market, by Region, Through 2023
Table 12: Global Market for Other Types of Opioid Drugs, by Region, Through 2023
Table 13: Global Opioid Drug Market, by Region, Through 2023
Table 14: North American Opioid Drug Market, by Product, Through 2023
Table 15: North American Opioid Drug Market, by Country, Through 2023
Table 16: Number of Prescriptions for Six of the Most Frequently Prescribed Opioids in Canada, 2012-2016
Table 17: European Opioid Drug Market, by Product, Through 2023
Table 18: European Opioid Drug Market, by Country, Through 2023
Table 19: Asia-Pacific Opioid Drug Market, by Product, Through 2023
Table 20: Asia-Pacific Opioid Drug Market, by Country, Through 2023
Table 21: South American Opioid Drug Market, by Product, Through 2023
Table 22: Middle East and African Opioid Drug Market, by Product, Through 2023
Table 23: List of ER/LA Opioid Drugs Subject to Opioid REMS, Branded Drugs, 2017
Table 24: List of ER/LA Opioid Drugs Subject to Opioid REMS, Generic Drugs, 2017
Table 25: Schedules Under the Controlled Substances Act
Table 26: Recent Initiatives to Control the Opioid Crisis in the U.S., 2018
Table 27: CDC Guidelines on Prescribing Opioids
Table 28: Opioid Drug Pipeline
Table 29: R&D Expenditures of Market Players, 2017
Table 30: Number of FDA Approvals (NDA and ANDA), 2005-2015
Table 31: Significant Industry Events in the Opioid Drug Market, 2015-2018
Table 32: Acura Pharmaceuticals: Opioid Drug Product Portfolio
Table 33: Allergan Plc: Opioid Drug Product Portfolio
Table 34: Apotex Inc.: Opioid Drug Product Portfolio
Table 35: Assertio Therapeutics: Opioid Drug Product Portfolio
Table 36: Biodelivery Sciences International Inc.: Opioid Drugs Product Portfolio
Table 37: Cipher Pharmaceuticals Inc.: Opioid Drugs Product Portfolio
Table 38: Collegium Pharmaceutical Inc.: Opioid Drug Product Portfolio
Table 39: Daiichi Sankyo Inc.: Opioid Drug Product Portfolio
Table 40: Egalet Corp.: Opioid Drugs Product Portfolio
Table 41: Endo International Plc: Opioid Drugs Product Portfolio
Table 42: Hikma Pharmaceuticals Plc: Opioid Drugs Product Portfolio
Table 43: Indivior Plc: Opioid Drug Product Portfolio
Table 44: Insys Therapeutics Inc.: Opioid Drug Product Portfolio
Table 45: Johnson & Johnson: Opioid Drug Product Portfolio
Table 46: KemPharm Inc.: Opioid Drugs Product Portfolio
Table 47: Lannett Co. Inc.: Opioid Drug Product Portfolio
Table 48: Lupin Ltd.: Opioid Drug Product Portfolio
Table 49: Mallinckrodt: Opioid Drug Product Portfolio
Table 50: Mylan NV: Opioid Drug Product Portfolio
Table 51: Orexo AB: Opioid Drug Product Portfolio
Table 52: Pfizer Inc.: Opioid Drugs Product Portfolio
Table 53: Purdue Pharma LP: Opioid Drug Product Portfolio
Table 54: Pernix Therapeutics: Opioid Drug Product Portfolio
Table 55: Sun Pharmaceuticals Industries Ltd.: Opioid Drugs Product Portfolio
Table 56: Teva Pharmaceutical Industries Ltd.: Opioid Drug Product Portfolio
Table 57: Acronyms Used in This Report
Summary Table: Global Opioid Drug Market, by Product, Through 2023
Table 1: Analgesic Effects of Drugs at Different Opioid Receptors
Table 2: Timeline of Selected FDA Activities and Events Related to Opioid Misuse and Abuse, 1911-2018
Table 3: FDA Approved Opioids with ADF Labeling
Table 4: Opioid Lawsuit Settlements, 2015-2027
Table 5: Global Opioid Drug Market, by Product, Through 2023
Table 6: Global Buprenorphine Drug Market, by Region, Through 2023
Table 7: Global Fentanyl Drug Market, by Region, Through 2023
Table 8: Global Hydrocodone Drug Market, by Region, Through 2023
Table 9: Global Morphine Drug Market, by Region, Through 2023
Table 10: Global Oxycodone Drug Market, by Region, Through 2023
Table 11: Global Tramadol Drug Market, by Region, Through 2023
Table 12: Global Market for Other Types of Opioid Drugs, by Region, Through 2023
Table 13: Global Opioid Drug Market, by Region, Through 2023
Table 14: North American Opioid Drug Market, by Product, Through 2023
Table 15: North American Opioid Drug Market, by Country, Through 2023
Table 16: Number of Prescriptions for Six of the Most Frequently Prescribed Opioids in Canada, 2012-2016
Table 17: European Opioid Drug Market, by Product, Through 2023
Table 18: European Opioid Drug Market, by Country, Through 2023
Table 19: Asia-Pacific Opioid Drug Market, by Product, Through 2023
Table 20: Asia-Pacific Opioid Drug Market, by Country, Through 2023
Table 21: South American Opioid Drug Market, by Product, Through 2023
Table 22: Middle East and African Opioid Drug Market, by Product, Through 2023
Table 23: List of ER/LA Opioid Drugs Subject to Opioid REMS, Branded Drugs, 2017
Table 24: List of ER/LA Opioid Drugs Subject to Opioid REMS, Generic Drugs, 2017
Table 25: Schedules Under the Controlled Substances Act
Table 26: Recent Initiatives to Control the Opioid Crisis in the U.S., 2018
Table 27: CDC Guidelines on Prescribing Opioids
Table 28: Opioid Drug Pipeline
Table 29: R&D Expenditures of Market Players, 2017
Table 30: Number of FDA Approvals (NDA and ANDA), 2005-2015
Table 31: Significant Industry Events in the Opioid Drug Market, 2015-2018
Table 32: Acura Pharmaceuticals: Opioid Drug Product Portfolio
Table 33: Allergan Plc: Opioid Drug Product Portfolio
Table 34: Apotex Inc.: Opioid Drug Product Portfolio
Table 35: Assertio Therapeutics: Opioid Drug Product Portfolio
Table 36: Biodelivery Sciences International Inc.: Opioid Drugs Product Portfolio
Table 37: Cipher Pharmaceuticals Inc.: Opioid Drugs Product Portfolio
Table 38: Collegium Pharmaceutical Inc.: Opioid Drug Product Portfolio
Table 39: Daiichi Sankyo Inc.: Opioid Drug Product Portfolio
Table 40: Egalet Corp.: Opioid Drugs Product Portfolio
Table 41: Endo International Plc: Opioid Drugs Product Portfolio
Table 42: Hikma Pharmaceuticals Plc: Opioid Drugs Product Portfolio
Table 43: Indivior Plc: Opioid Drug Product Portfolio
Table 44: Insys Therapeutics Inc.: Opioid Drug Product Portfolio
Table 45: Johnson & Johnson: Opioid Drug Product Portfolio
Table 46: KemPharm Inc.: Opioid Drugs Product Portfolio
Table 47: Lannett Co. Inc.: Opioid Drug Product Portfolio
Table 48: Lupin Ltd.: Opioid Drug Product Portfolio
Table 49: Mallinckrodt: Opioid Drug Product Portfolio
Table 50: Mylan NV: Opioid Drug Product Portfolio
Table 51: Orexo AB: Opioid Drug Product Portfolio
Table 52: Pfizer Inc.: Opioid Drugs Product Portfolio
Table 53: Purdue Pharma LP: Opioid Drug Product Portfolio
Table 54: Pernix Therapeutics: Opioid Drug Product Portfolio
Table 55: Sun Pharmaceuticals Industries Ltd.: Opioid Drugs Product Portfolio
Table 56: Teva Pharmaceutical Industries Ltd.: Opioid Drug Product Portfolio
Table 57: Acronyms Used in This Report
LIST OF FIGURES
Summary Figure: Global Opioid Drug Market Share, by Product, 2017
Figure 1: Opioid Misuse Among People 12 or Older, by Age Group, 2015
Figure 2: Prescription Pain Relief Misuse Among People 12 or Older, by Age Group, 2015
Figure 3: Number of Drug Overdose Deaths in the U.S., 2010-2016
Figure 4: Global Opioid Drug Market Share, by Product, 2017
Figure 5: Global Buprenorphine Drug Market, 2017-2023
Figure 6: Global Buprenorphine Drug Market, by Region, 2017-2023
Figure 7: Global Fentanyl Drug Market, 2017-2023
Figure 8: Global Fentanyl Drug Market, by Region, 2017-2023
Figure 9: Global Hydrocodone Drug Market, 2017-2023
Figure 10: Global Hydrocodone Drug Market, by Region, 2017-2023
Figure 11: Global Morphine Drug Market, 2017-2023
Figure 12: Global Morphine Drug Market, by Region, 2017-2023
Figure 13: Global Oxycodone Drug Market, 2017-2023
Figure 14: Global Oxycodone Drug Market, by Region, 2017-2023
Figure 15: Global Tramadol Drug Market, 2017-2023
Figure 16: Global Tramadol Drug Market, by Region, 2017-2023
Figure 17: Global Market for Other Types of Opioid Drugs, 2017-2023
Figure 18: Global Market for Other Types of Opioid Drugs, by Region, 2017-2023
Figure 19: Global Opioid Drug Market Share, by Region, 2017
Figure 20: North American Opioid Drug Market Share, by Product, 2017
Figure 21: North American Opioid Drug Market Share, by Country, 2017
Figure 22: U.S. Opioid Drug Market, 2017-2023
Figure 23: Total Number of Opioid Prescriptions Dispensed, U.S, 2010-2017
Figure 24: Number of Drug Overdose Deaths, U.S., 2010-2016
Figure 25: Canadian and Mexican Market for Opioid Drugs, 2017-2023
Figure 26: European Opioid Drug Market Share, by Product, 2017
Figure 27: European Opioid Drug Market Share, by Country, 2017
Figure 28: German Opioid Drug Market, 2017-2023
Figure 29: U.K. Opioid Drug Market, 2017-2023
Figure 30: French Opioid Drug Market, 2017-2023
Figure 31: Rest of European Market for Opioid Drugs, 2017-2023
Figure 32: Asia-Pacific Opioid Drug Market Share, by Product, 2017
Figure 33: Asia-Pacific Opioid Drug Market Share, by Country, 2017
Figure 34: Japanese Opioid Drug Market, 2017-2023
Figure 35: Chinese Opioid Drug Market, 2017-2023
Figure 36: Indian Opioid Drug Market, 2017-2023
Figure 37: Rest of Asia-Pacific Opioid Drug Market, 2017-2023
Figure 38: South American Opioid Drug Market, 2017-2023
Figure 39: South American Opioid Drug Market Share, by Product, 2017
Figure 40: Middle East and African Market for Opioid Drugs, 2017-2023
Figure 41: Middle East and African Opioid Drug Market Share, by Product, 2017
Figure 42: Allergan Plc: Annual Revenue, 2013-2017
Figure 43: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 44: Assertio Therapeutics: Revenue, 2013-2017
Figure 45: Biodelivery Sciences International Inc.: Annual Revenue, 2013-2017
Figure 46: Endo International Plc: Revenue, 2013-2017
Figure 47: Endo International Plc: Revenue Share, by Business Unit, 2017
Figure 48: Lannett Co. Inc.: Financial Performance, 2015-2017
Figure 49: Mylan NV: Financial Performance, 2014-2017
Figure 50: Mylan NV: Revenue Share, by Region, 2017
Figure 51: Sun Pharmaceuticals Industries Ltd.: Financial Performance, 2015-2017
Figure 52: Teva Pharmaceutical Industries Ltd.: Financial Performance, 2015-2017
Figure 53: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 54: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
Summary Figure: Global Opioid Drug Market Share, by Product, 2017
Figure 1: Opioid Misuse Among People 12 or Older, by Age Group, 2015
Figure 2: Prescription Pain Relief Misuse Among People 12 or Older, by Age Group, 2015
Figure 3: Number of Drug Overdose Deaths in the U.S., 2010-2016
Figure 4: Global Opioid Drug Market Share, by Product, 2017
Figure 5: Global Buprenorphine Drug Market, 2017-2023
Figure 6: Global Buprenorphine Drug Market, by Region, 2017-2023
Figure 7: Global Fentanyl Drug Market, 2017-2023
Figure 8: Global Fentanyl Drug Market, by Region, 2017-2023
Figure 9: Global Hydrocodone Drug Market, 2017-2023
Figure 10: Global Hydrocodone Drug Market, by Region, 2017-2023
Figure 11: Global Morphine Drug Market, 2017-2023
Figure 12: Global Morphine Drug Market, by Region, 2017-2023
Figure 13: Global Oxycodone Drug Market, 2017-2023
Figure 14: Global Oxycodone Drug Market, by Region, 2017-2023
Figure 15: Global Tramadol Drug Market, 2017-2023
Figure 16: Global Tramadol Drug Market, by Region, 2017-2023
Figure 17: Global Market for Other Types of Opioid Drugs, 2017-2023
Figure 18: Global Market for Other Types of Opioid Drugs, by Region, 2017-2023
Figure 19: Global Opioid Drug Market Share, by Region, 2017
Figure 20: North American Opioid Drug Market Share, by Product, 2017
Figure 21: North American Opioid Drug Market Share, by Country, 2017
Figure 22: U.S. Opioid Drug Market, 2017-2023
Figure 23: Total Number of Opioid Prescriptions Dispensed, U.S, 2010-2017
Figure 24: Number of Drug Overdose Deaths, U.S., 2010-2016
Figure 25: Canadian and Mexican Market for Opioid Drugs, 2017-2023
Figure 26: European Opioid Drug Market Share, by Product, 2017
Figure 27: European Opioid Drug Market Share, by Country, 2017
Figure 28: German Opioid Drug Market, 2017-2023
Figure 29: U.K. Opioid Drug Market, 2017-2023
Figure 30: French Opioid Drug Market, 2017-2023
Figure 31: Rest of European Market for Opioid Drugs, 2017-2023
Figure 32: Asia-Pacific Opioid Drug Market Share, by Product, 2017
Figure 33: Asia-Pacific Opioid Drug Market Share, by Country, 2017
Figure 34: Japanese Opioid Drug Market, 2017-2023
Figure 35: Chinese Opioid Drug Market, 2017-2023
Figure 36: Indian Opioid Drug Market, 2017-2023
Figure 37: Rest of Asia-Pacific Opioid Drug Market, 2017-2023
Figure 38: South American Opioid Drug Market, 2017-2023
Figure 39: South American Opioid Drug Market Share, by Product, 2017
Figure 40: Middle East and African Market for Opioid Drugs, 2017-2023
Figure 41: Middle East and African Opioid Drug Market Share, by Product, 2017
Figure 42: Allergan Plc: Annual Revenue, 2013-2017
Figure 43: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 44: Assertio Therapeutics: Revenue, 2013-2017
Figure 45: Biodelivery Sciences International Inc.: Annual Revenue, 2013-2017
Figure 46: Endo International Plc: Revenue, 2013-2017
Figure 47: Endo International Plc: Revenue Share, by Business Unit, 2017
Figure 48: Lannett Co. Inc.: Financial Performance, 2015-2017
Figure 49: Mylan NV: Financial Performance, 2014-2017
Figure 50: Mylan NV: Revenue Share, by Region, 2017
Figure 51: Sun Pharmaceuticals Industries Ltd.: Financial Performance, 2015-2017
Figure 52: Teva Pharmaceutical Industries Ltd.: Financial Performance, 2015-2017
Figure 53: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 54: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
